Bruker expands Indian operations
Bruker (Massachusetts, USA) has built on its 30-year history in India by opening two new centres of excellence in Mumbai and Bengaluru.
Bruker (Massachusetts, USA) has built on its 30-year history in India by opening two new centres of excellence in Mumbai and Bengaluru. During this time, Bruker has established itself in many of India’s major cities including New Delhi, Mumbai, Bengaluru, Chennai, Kolkata, Lucknow and Hyderabad.
The new centres of excellence will offer customer support for scientific and analytical instrumentation for the growing Indian market. The locations ofthe centres were selected based on their proximity to major academic, government and industrial research laboratories.
Dr Frank Laukien, Bruker’s President and CEO, commented: “With this significant investment in our two new centres of excellence, Bruker has taken a major step forward in India to provide highest‑level support for the outstanding and rapidly growing Indian research, industrial and clinical communities.”
For more information,please visit:
www.bruker.com
This story originally appeared in The Column. Click here to view that issue.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
